Asahi Kasei is consistently pursuing its strategy of building a focused, sustainable specialty pharmaceutical platform for immunocompromised and medically complex patient groups
Asahi Kasei Pharma receives worldwide exclusive rights for the research, development, manufacturing, and marketing of the active ingredients
Arcellx develops innovative immunotherapies for cancer and other incurable diseases
New partnership combines Shilpa Biologicals’ development and manufacturing capabilities with SteinCares’ regional commercialization platform
Sugemalimab, developed using CStone’s OmniRat transgenic platform, is a fully human IgG4 monoclonal antibody designed to minimize immunogenicity and toxicity
The innovative eyedrop targets inflammation and pain following ocular surgery
The announcement follows a record-setting $1.2 million accelerated LineaDNA order
Liraglutide is a drug-device combination formulation used in the treatment of chronic weight management
The program offers selected participants advanced access to Promise Bio’s broad-epiproteomic platform
The move follows encouraging Phase I data and a series of regulatory wins from the U.S. Food and Drug Administration
Subscribe To Our Newsletter & Stay Updated
